Killer immune cell culturing method and application thereof

Abstract

The invention discloses a killer immune cell culturing method and application thereof. The method is a novel technology for culturing, activating and amplifying peripheral blood mononuclear immune cells into tumor killer cells, and the tumor killing capacity of T cells is enhanced by adding a PD-1 antibody to inhibit combination of PD-1 on the T cells and tumor cells in the late period of cell culturing or before transfusion through the characteristic that the inhibition effect of an immunosuppression target point on the immune cell functions is inhibited by adding an immune check point antibody; the cells cultured through the method have CTL cells which are targeted on the tumor antigen specificity in high proportion and also have the high capacity on killing the tumor cells. In this way, not only is the defect of an existing technology on the CTL cell culturing effect overcome, but also limitation of an immune checking point on the T cell functions is fully utilized and relieved, therefore, the tumor cell killing capacity of the prepared cells is improved, and the efficacy of the prepared cells on clinical cancer treatment is improved.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a method for cultivating killer immune cells and its application. Background technique [0002] Malignant tumors are the most serious diseases that endanger human health. Every year, about 3 million people in the country are diagnosed with new tumors, and more than 2 million people die of cancer. Although it can be treated by surgery, radiotherapy, and chemotherapy, most patients still die of tumor recurrence and metastasis. Therefore, how to remove the residual tiny tumor tissue or tumor cells is one of the problems to be solved in modern tumor immunology. Since the root cause of cancer is the uncontrolled growth of tumor cells escaping the monitoring of immune cells, improving the recognition and killing of tumor cells by the immune system will fundamentally remove the tumor. With the clinical application and promotion of new technologies, immunotherapy has gradually beco...

AI Technical Summary

Problems solved by technology

[0005] The current clinical use of CTL to treat cancer generally has the disadvantages of low specificity and low efficacy after reinfusion

Images